Matthias Müllenbeck: What if we paid doctors to keep people healthy?
מתיאס מולנבק: מה אם היינו משלמים לרופאים לשמור על בריאותם של אנשים?
As the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology. Full bio
Double-click the English transcript below to play the video.
fell off the evening before.
I'm sitting in a dentist's chair.
על כסא רופא השיניים.
so that I can get rid of my pain,
שאפטר מהכאב,
of a titanium implant surgery.
של ניתוח שתלים מטיטניום.
a damaged tooth
may add up to 10,000 US dollars.
להגיע ל 10,000 דולר.
that could be earned with me
שהוא יכל להרוויח ממני
for my dentist?
רופא השיניים שלי?
wasn't an isolated case.
estimated that in the United States,
העריך שבארצות הברית,
surgical procedures --
and pacemaker implantations,
options had not been fully exploited
עוד לא מוצו עד תום
in other countries,
if you go to a doctor in the US,
בארצות הברית,
to be subjected to a surgical intervention
an immediate need for it.
to run such unnecessary procedures?
ניתוחים לא נחוצים?
health care systems themselves
certain procedures or treatments.
או טיפולים מסוימים.
reimburse practitioners
את הרופאים
of treatments performed,
that tempts some practitioners
מפתה רופאים מסוימים
surgical treatments
other treatment options.
started to implement
health care systems' architecture
הבריאות כיום
of a disease in the first place
מחלות מלכתחילה
applied to a patient
system's architecture --
of the incentive structure.
for keeping their customers healthy
המטופלים שלהם בריאים
once people are already sick.
שאנשים כבר חולים.
that largely cares for the sick,
מטפלת בחולים,
people once they have become sick
הופכים להיות חולים
before they get sick.
of all those involved --
אלה המעורבים --
to pharmaceutical and medical companies --
לחברות תרופות ורפואיות --
ultimately sells:
reimburse practitioners
performed on a patient
individual is kept healthy
to an insurance company
תשלום בריאות לחברות הביטוח
is kept healthy
of acute medical intervention.
התערבות רפואית רצינית.
any further monetary compensation
to treat the disease of that individual,
במחלה של אותו אדם,
for every evidence-based treatment option
טיפול המבוססת על עובדות
will be paid again.
their customers healthy,
הלקוחות שלהם בריאים,
any unnecessary medical interventions
רפואית מיותרת
that eventually become sick.
שבסופו של דבר יחלו.
to treat the sick will be,
for all parties being involved
לכל המעורבים
structure shifts, now,
health care system
and singular treatment options,
to stay healthy and live long.
זמן ארוך יותר.
to share their health data
המידע הרפואי שלהם
understands early enough
to their health is needed.
cardiometabolic profiling
קרדיו-מטאבולי
and general practitioners,
and their physical activity --
והפעילות הגופנית שלהם --
individual high-risk disease.
גבוה לאותו אדם.
data analysis
of sensor technologies
of the individual health status possible.
מצבו הרפואי של האדם לאפשרי.
by devices like this
באמצעות מכשירים כמו זה
tumor DNA in your bloodstream
for such monitoring technologies.
in certain oncological diseases
במחלות אונקולוגיות מסוימות
is diagnosed too late
that could potentially have cured them
באופן פוטנציאלי לרפא אותם
been detected earlier.
based on a few milliliters of blood,
בהתבסס על כמה מיליליטרים של דם,
of circulating tumor DNA
detection can have
for non-small cell lung cancer
בקרב חולי סרטן ריאות
which is early, is 49 percent.
הוא 49 אחוזים.
at stage four, which is late,
המאוחר,
to prevent a large number of deaths
for circulating tumor DNA
דנא סרטני
a manageable disease,
למחלה טיפולית,
can likely be increased.
החיוביות יעלו.
had a single chronic disease,
מחלה כרונית כלשהי
of the $3 trillion US health care budget
האמריקאי של 3 טריליון דולר
such chronic diseases.
to reduce this 86 percent,
להקטין את 86 האחוזים האלה
not reacted and changed already?
ושינו את הנהלים שלהן?
is a sick care system
that focuses on prevention
in the system to change.
to shift budgets and policies
and non-financial incentives.
ולא כלכליים.
a regulatory framework
of personal health data
stringent and sensible.
pharmaceutical and medical companies
חברות תרופות ורפואה
and, most important,
the willingness and motivation
in a sustained way,
באופן בר קיימא,
the health data on a constant basis.
על בסיס קבוע.
within the health care industry today
בתוך תעשיית הבריאות כיום
more diseases in the first place
the onset of certain preventable diseases
מחלות מסוימות שניתן למנוע אותן
and healthier lives for more people.
עבור יותר אנשים.
that we need to initiate that change
ליזום את השינוי
ABOUT THE SPEAKER
Matthias Müllenbeck - Business developerAs the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology.
Why you should listen
Throughout his career in various roles at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck worked on strategic asset, technology and diagnostic-licensing deals and on bringing to market innovative chemical products. He holds a PhD in immunology from the Humboldt University in Berlin and has worked at the Max-Planck Institute for infection biology in Berlin, at Bayer, and at the Albert-Schweizer Hospital in Lambarané, Gabon.
Matthias Müllenbeck | Speaker | TED.com